CYP2D6
ENSG00000100197
Target class
Enzyme
Chromosome
22
- Chemical probe available
- Yes
- Target name
- CYP2D6
- Gene name
- Cytochrome P450 family 2 subfamily D member 6 (gene/pseudogene)
- Gene symbol
- CYP2D6
- Protein name
- Cytochrome P450 2D6 (EC 1.14.14.-) (CYPIID6) (Cholesterol 25-hydroxylase) (Cytochrome P450-DB1) (Debrisoquine 4-hydroxylase)
- CPD6
- P450-DB1
- CYP2D
- P450C2D
- CYP2DL1
- CYP2D7P2
- CYP2D7BP
- CYP2D8P2
- CYP2D7AP
- Gene biotype
- Protein coding
- Gene family
- Cytochrome P450 family 2
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 48
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 215.32
- Tissue specificity (Gini)
- 0.728
- Tissue specificity (tau)
- 0.986
- KEGG gene identifiers
- hsa:1565
- Protein interaction confidence
- 0.909667
- Protein interaction partners
- 48
- R-HSA-211935
- R-HSA-211958
- R-HSA-211981
- R-HSA-211999
- R-HSA-9027307
- R-HSA-9749641
- End position
- 42131236
- Start position
- 42125962
- Chromosome
- 22
- Strand
- Reverse
- Endoplasmic reticulum membrane
- Peripheral membrane protein. Microsome membrane
- Peripheral membrane protein.
- Golgi apparatus
Publication evidence
- PubMed 21576599
- Tissue specificity (tau)
- 0.986304
- Expression inequality (Gini)
- 0.728107
Expression in transcripts per million
- Liver
- 215.32
- Small Intestine - Terminal Ileum
- 9.65
- Thyroid
- 9.39
- Brain - Cerebellum
- 8.94
- Pituitary
- 8.91
Expression in transcripts per million
- Liver215.32
- Small Intestine - Terminal Ileum9.65
- Thyroid9.39
- Brain - Cerebellum8.94
- Pituitary8.91
- Testis8.39
- Brain - Cerebellar Hemisphere6.55
- Prostate5.78
- Ovary5.44
- Brain - Nucleus accumbens (basal ganglia)3.89
- Vagina3.85
- Nerve - Tibial3.82
- Skin - Not Sun Exposed (Suprapubic)3.55
- Kidney - Medulla3.54
- Cervix - Endocervix3.49
- Spleen3.46
- Uterus3.33
- Brain - Hypothalamus3.3
- Skin - Sun Exposed (Lower leg)3.13
- Cervix - Ectocervix3.03
- Esophagus - Mucosa3.02
- Brain - Caudate (basal ganglia)2.86
- Fallopian Tube2.83
- Minor Salivary Gland2.81
- Colon - Transverse2.68
And 29 more, listed on the interactive page.
- GO:0006805
- GO:0008202
- GO:0008210
- GO:0009804
- GO:0009820
- GO:0009822
- GO:0016098
- GO:0033076
- GO:0042178
- GO:0042572
- GO:0042759
- GO:0070989
- GO:0090350
- GO:0005739
- GO:0005783
- GO:0005789
- GO:0004497
- GO:0016491
- GO:0016712
- GO:0020037
- GO:0062187
- GO:0062188
- GO:0062189
regulation of catalytic activity
Studies
- biochemical: NVS_ADME_hCYP2D6, is one of one assay component(s) measured or calculated from the NVS_ADME_hCYP2D6 assay. It is designed to make measurements of enzyme activity, a form of enzyme reporter, as detected with fluorescence intensity signals by Fluorescence technology.
Biological samples
- cell-free
Evidence source
Related records
Trials (81)
- A Clinical Study to Evaluate the Effects of Akkermansia Muciniphila and Berberine on Prediabetes Among Obese Subjects.
- A Clinical Trial to Evaluate MK-4208/Embibatinib in Healthy Adult Participants (MK-4208-001/Embibatinib-1014)
- A Comparison of Antiarrhythmic Drug Therapy and Radio Frequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation
- A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy Participants
- A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323.
- A Mechanistic Randomized Controlled Trial on the Cardiovascular Effect of Berberine
- A Phase 1 Study Comparing AVP-786 With AVP-923
- A Phase 1, Drug Interaction Study Between AVP-786 and Paroxetine and Between AVP-786 and Duloxetine in Healthy Subjects
- A Phase-1 Study to Assess the Pharmacokinetics, Safety and Tolerability of AVP-786 in Healthy Volunteers
- A Single and Multiple Ascending Doses, Relative Bioavailability, Food Effect, and Drug-Drug Interaction Study of NX-5948 in Healthy Volunteers
- A Study of Imlunestrant (LY3484356) in Female Healthy Participants
- A Study to Assess the Effect of Voriconazole and Quinidine on the Pharmacokinetics of a Single Dose of Repotrectinib in Healthy Participants
- A Study to Evaluate the Effect of Genotype on LY2216684
- A Study to Investigate the Effect of Food on Balcinrenone/Dapagliflozin Pharmacokinetics in Fed and Fasted State and Pharmacokinetics of Balcinrenone When Dosed With a P-gp Inhibitor in Healthy Participants.
- A Study to Investigate the Pharmacokinetics of AZD2389 in Healthy Participants When Administered Alone and in Combination With Quinidine
- Anti-platelet Effect of Berberine in Patients After Percutaneous Coronary Intervention
- Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
- Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
- Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM)
- Berberine as Adjuvant Treatment for Schizophrenia Patients
Drugs (2)
- Berberine
- Quinidine